Drug Trial Radar · NCT07847411
Study of Velaglucerase Beta ERT in Children With Gaucher Disease
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Sep 16, 2026
Primary completion
Feb 25, 2028
Study completion Feb 25, 2028
Sponsor
- Lead sponsor
- CANbridge Life Sciences Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, multicenter, open-label, single-arm study to evaluate the safety, efficacy, PK, PD, and immunogenicity of velaglucerase beta in untreated children with GD1 or GD3 for 39 weeks.
Conditions
- Gaucher Disease
- Gaucher Disease Type 1
- Gaucher Disease Type 3
Interventions
Velaglucerase betaDrug
All subjects will receive velaglucerase beta 60 U/kg IV Q2W for 37 weeks with two weeks of follow-up through Week 39 (9 months).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary EndpointsTime frame: From Baseline to Week 39
- Mean percent change in MN spleen volumeTime frame: From Baseline to Week 39
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Room 202, 2nd Floor, 780 Cailun Road, Pilot Free Trade Zone
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.